CMPS Stock Overview
Operates as a mental health care company in the United Kingdom and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
COMPASS Pathways plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.41 |
| 52 Week High | US$12.75 |
| 52 Week Low | US$4.05 |
| Beta | 2.3 |
| 11 Month Change | -29.78% |
| 3 Month Change | -44.88% |
| 1 Year Change | -27.23% |
| 33 Year Change | -86.57% |
| 5 Year Change | n/a |
| Change since IPO | -84.79% |
Recent News & Updates
Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Nov 01Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
Aug 19Recent updates
Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Nov 01Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
Aug 19Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
Jul 08Psychedelics Closer To Commercialization; Compass Far And Away The Leader
May 23COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Apr 25Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Feb 08Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth
Dec 06
Booker again pushes for easier access to psychedelics for terminally ill patients
Oct 19Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation
Aug 13COMPASS Pathways And The Trillion Dollar Opportunity
Aug 11COMPASS Pathways ADS Q2 2022 Earnings Preview
Aug 03COMPASS Pathways names new CEO
Jul 19Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy
Jun 30We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely
Apr 28Checking In On Compass Pathways
Mar 02We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth
Dec 29Compass Pathways: Psychedelics For Mental Health
Nov 23Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy
Sep 17COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
Sep 15Compass Pathways: Huge Growth Potential, But I'm Cautious
Jun 04COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
May 25COMPASS Pathways raises $144M capital via equity offering
Apr 30COMPASS Pathways launches public offering
Apr 27We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate
Feb 08Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront
Jan 01Compass Pathways: Risky And Overvalued
Dec 18What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?
Dec 18Shareholder Returns
| CMPS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.4% | 2.5% | 2.2% |
| 1Y | -27.2% | 16.1% | 31.6% |
Return vs Industry: CMPS underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: CMPS underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| CMPS volatility | |
|---|---|
| CMPS Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CMPS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CMPS's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 186 | Kabir Nath | compasspathways.com |
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
COMPASS Pathways plc Fundamentals Summary
| CMPS fundamental statistics | |
|---|---|
| Market cap | US$301.74m |
| Earnings (TTM) | -US$144.32m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.1x
P/E RatioIs CMPS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMPS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$144.32m |
| Earnings | -US$144.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.11 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 15.4% |
How did CMPS perform over the long term?
See historical performance and comparison